DexCom's stock surged by 6.59%, driven by an optimistic growth outlook of at least 10% annually through 2030 alongside the anticipation of its G7 continuous glucose monitoring system launch. The company's market cap now stands at approximately $23.5 billion, buoyed by recent improvements in free cash flow margins and a move to discontinue its G6 system. This positive momentum reflects the impact of a new strategic partnership with Elliott Management aimed at enhancing operations and profitability.
“DexCom · has a market cap of · $23.5 billion · true”
“DexCom · averaged an organic revenue growth of · 12.5% · true”
“DexCom · has a free cash flow margin increase of · 26 percentage points · true”
“Dexcom · started coverage · Buy rating · true”
“Dexcom · price target · $77 · true”
“Dexcom · announced availability of G7 · January 2026 · true”
“Dexcom · plans to discontinue · G6 system · true”
“DexCom · has · market cap · $23.5 billion”
“DexCom · has · average organic revenue growth · 12.5%”
“DexCom · has · free cash flow margin increase · 26 percentage points”
“DexCom · trades at · forward P/E · 22.9x”
“DexCom · closed at · US$61.14 · 2.8% gain over the last week”
